Search research articles
Contact Us
Filters
Showing results (151-160 of 182) with videos related to
Page
of 19
Sort By:
Experimental Biology and Medicine (Maywood, N.J.)
|
August 5, 2025
Functional antibody responses to SARS-CoV-2 variants before and after booster vaccination among adults in Ghana
F D Partey, A N A Pobee, I K Damptey, et al.
Pharmacogenetics and Genomics
|
March 20, 2019
An initial genetic analysis of gemcitabine-induced high-grade neutropenia in pancreatic cancer patients in CALGB 80303 (Alliance)
Federico Innocenti, Chen Jiang, Alexander B Sibley, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 16, 2005
Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas
Howard A Burris, Herbert I Hurwitz, E Claire Dees, et al.
Cancer
|
February 3, 2015
Clinical outcomes of patients with advanced gastrointestinal stromal tumors: safety and efficacy in a worldwide treatment-use trial of sunitinib
Peter Reichardt, Yoon-Koo Kang, Piotr Rutkowski, et al.
Nature Clinical Practice. Oncology
|
April 28, 2007
Complete pathological response to bevacizumab and chemoradiation in advanced rectal cancer
Christopher G Willett, Dan G Duda, Emmanuelle di Tomaso, et al.
Investigational New Drugs
|
November 1, 2013
Phase I study of dasatinib in combination with capecitabine, oxaliplatin and bevacizumab followed by an expanded cohort in previously untreated metastatic colorectal cancer
John H Strickler, Shannon McCall, Andrew B Nixon, et al.
JAMA Network Open
|
February 18, 2022
Assessment of Capecitabine and Bevacizumab With or Without Atezolizumab for the Treatment of Refractory Metastatic Colorectal Cancer: A Randomized Clinical Trial
Niharika B Mettu, Fang-Shu Ou, Tyler J Zemla, et al.
Nucleic Acids Research
|
December 26, 2001
MMDB: Entrez's 3D-structure database
Yanli Wang, John B Anderson, Jie Chen, et al.
Cancer Chemotherapy and Pharmacology
|
November 17, 2010
A phase I study of bevacizumab (B) in combination with everolimus (E) and erlotinib (E) in advanced cancer (BEE)
Karen E Bullock, William P Petros, Islam Younis, et al.
The Oncologist
|
March 15, 2013
A phase II study of capecitabine, oxaliplatin, and bevacizumab in the treatment of metastatic esophagogastric adenocarcinomas
Hope E Uronis, Johanna C Bendell, Ivy Altomare, et al.
Page
of 19
Search research articles
Search
Showing results (151-160 of 182) with videos related to
Sort By:
Page
of 19
Experimental Biology and Medicine (Maywood, N.J.)
|
August 5, 2025
Functional antibody responses to SARS-CoV-2 variants before and after booster vaccination among adults in Ghana
F D Partey, A N A Pobee, I K Damptey, et al.
Pharmacogenetics and Genomics
|
March 20, 2019
An initial genetic analysis of gemcitabine-induced high-grade neutropenia in pancreatic cancer patients in CALGB 80303 (Alliance)
Federico Innocenti, Chen Jiang, Alexander B Sibley, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 16, 2005
Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas
Howard A Burris, Herbert I Hurwitz, E Claire Dees, et al.
Cancer
|
February 3, 2015
Clinical outcomes of patients with advanced gastrointestinal stromal tumors: safety and efficacy in a worldwide treatment-use trial of sunitinib
Peter Reichardt, Yoon-Koo Kang, Piotr Rutkowski, et al.
Nature Clinical Practice. Oncology
|
April 28, 2007
Complete pathological response to bevacizumab and chemoradiation in advanced rectal cancer
Christopher G Willett, Dan G Duda, Emmanuelle di Tomaso, et al.
Investigational New Drugs
|
November 1, 2013
Phase I study of dasatinib in combination with capecitabine, oxaliplatin and bevacizumab followed by an expanded cohort in previously untreated metastatic colorectal cancer
John H Strickler, Shannon McCall, Andrew B Nixon, et al.
JAMA Network Open
|
February 18, 2022
Assessment of Capecitabine and Bevacizumab With or Without Atezolizumab for the Treatment of Refractory Metastatic Colorectal Cancer: A Randomized Clinical Trial
Niharika B Mettu, Fang-Shu Ou, Tyler J Zemla, et al.
Nucleic Acids Research
|
December 26, 2001
MMDB: Entrez's 3D-structure database
Yanli Wang, John B Anderson, Jie Chen, et al.
Cancer Chemotherapy and Pharmacology
|
November 17, 2010
A phase I study of bevacizumab (B) in combination with everolimus (E) and erlotinib (E) in advanced cancer (BEE)
Karen E Bullock, William P Petros, Islam Younis, et al.
The Oncologist
|
March 15, 2013
A phase II study of capecitabine, oxaliplatin, and bevacizumab in the treatment of metastatic esophagogastric adenocarcinomas
Hope E Uronis, Johanna C Bendell, Ivy Altomare, et al.
Page
of 19